Cancer: Drugs

(asked on 19th July 2017) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, when will companies following a recommendation for use from the Cancer Drugs Fund be able to access Cancer Drugs Fund funding for a drug which they have previously been making available to the NHS free of charge by means of the Early Access to Medicines Scheme.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 6th September 2017

Under the new arrangements for the appraisal and funding of cancer drugs introduced in July 2016, the National Institute for Health and Care Excellence (NICE) aims to publish draft recommendations on the use of all cancer drugs before licensing. Where NICE’s draft guidance recommends use of the drug for routine commissioning or for use through the Cancer Drugs Fund, NHS England will make Cancer Drugs Fund funding available for its use in National Health Service patients in line with NICE’s recommendations from the point of licensing. There should therefore be no gap in the availability of cancer drugs recommended by NICE that had previously been made available before licensing under the Early Access to Medicines Scheme.

Reticulating Splines